Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-09-16 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2024年股权激励计划预留授予公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the 2024 equity incentive plan reserved grant by Chengdu Oukang Pharmaceutical Co., Ltd. It includes information about board and supervisory meetings, approval processes, legal opinions, details of the stock incentive plan including number of shares, prices, vesting periods, performance targets, and impact on financials. The document is not a full financial report but a corporate announcement about a capital-related event specifically about stock-based compensation and equity incentive plans. It does not contain quarterly or annual financial statements or earnings highlights. It is not a proxy statement or voting result announcement. The content fits best under Capital/Financing Update (CAP) as it relates to equity incentive plan grants and share issuance to employees and management. The document length is sufficient and contains substantive details about the equity incentive plan grant, not just a brief notice or report publication announcement.
2025-09-16 Chinese
2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary shareholders meeting of Chengdu Oukang Pharmaceutical Co., Ltd. It includes meeting details, attendance, voting results on various proposals, and legal opinions confirming the meeting's legality and validity. The content focuses on the official voting results of shareholder decisions on multiple corporate governance and operational matters. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a presentation or a proxy solicitation but an official declaration of voting results from a shareholders meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4304 characters, which is sufficient to contain detailed voting results rather than a mere announcement of a report publication (RPA).
2025-09-16 Chinese
2024年股权激励计划预留授予激励对象名单（授予日）
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Chengdu Oukang Pharmaceutical Co., Ltd. regarding the 2024 equity incentive plan reserved grant list. It details the allocation of restricted stock to incentive recipients, including board secretary and financial director, and core employees. The document includes specific stock quantities, percentages of total shares, and notes on the plan's terms. It is a formal announcement of a share-based incentive plan allocation rather than a full financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is relatively short (1013 characters) and serves as a notification of share-based incentive allocations. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including equity incentive plans.
2025-09-16 Chinese
第四届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 4th Board of Directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details meeting attendance, agenda items, voting results, and organizational changes such as adjustments to the company structure and stock incentive plans. There is no financial data or report content, but rather a disclosure of board decisions and governance matters. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related governance decisions. The document length is short and focused on board resolutions, not a full report or financial statement.
2025-09-16 Chinese
公司章程
Governance Information Classification · 95% confidence The document is titled "章程" which translates to "Articles of Association" or "Company Bylaws". It contains detailed provisions about the company's organization, shareholder rights, board structure, management, share issuance, shareholder meetings, and other governance matters. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Beijing Stock Exchange rules. The content is a comprehensive governance document outlining internal rules and procedures rather than financial results, audit opinions, or meeting announcements. It is not a report of financial performance, nor an announcement or transcript. Therefore, the document fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-09-16 Chinese
独立董事专门会议关于2024年股权激励计划预留授予事项的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Chengdu Oukang Pharmaceutical Co., Ltd. regarding the independent directors' special meeting opinion on the 2024 equity incentive plan reserved grant matters. It includes legal and regulatory references related to stock incentive plans and confirms the approval of a restricted stock grant to certain incentive recipients. The document is short (877 characters) and focuses on the approval and verification of equity incentive plan details rather than presenting full financial data or detailed financial statements. It is not an annual report, earnings release, or management report. It is also not a proxy solicitation or voting result announcement. The content fits best with a Capital/Financing Update (CAP) as it relates to equity incentive grants, which affect capital structure and financing activities. Therefore, the classification is CAP with high confidence.
2025-09-16 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.